Facteur Thymique Serique, FTS
Evidence Grade C — Moderate human evidence. 373 published studies, 173 human. 0 registered clinical trials.
Thymulin is a naturally occurring hormone produced by the thymus gland, unique in that its biological activity completely depends on binding zinc. Blood levels decline progressively with age to nearly undetectable levels by the fifth decade of life. No controlled human therapeutic trials have been conducted, though the basic science — established across multiple independent laboratories — is well-regarded.
373 published studies: 173 human, 178 animal, 103 in-vitro, 66 reviews
Thymulin has no marketing authorisation. No controlled human therapeutic trials have been conducted. Animal studies have investigated the relationship between zinc supplementation, thymulin restoration, and immune function in aged subjects.
Circulating thymulin levels decline progressively with age to nearly undetectable levels by the fifth decade of life. Research suggests this decline is partially reversible with zinc supplementation in animal models, but the therapeutic implications of these observations for human health have not been established through clinical trials.
Research suggests thymulin, when bound to zinc, may influence T-cell differentiation and maturation. Its biological activity is completely abolished without zinc, making the zinc-peptide complex the functional unit. Animal studies have investigated the relationship between age-related zinc deficiency, declining thymulin levels, and immune dysfunction.
Research suggests thymulin's mechanism is well characterised, with multiple independent research groups confirming its zinc-dependence and immune-modulating properties. Animal studies show that zinc supplementation can partially reverse age-related thymulin decline and associated immune dysfunction. Despite compelling preclinical evidence and a well-documented age-related decline that provides biological rationale for supplementation, no human interventional trials of thymulin administration exist. The therapeutic window, optimal dosing, and clinical significance remain entirely undefined in humans.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Corticotropin is marketed as H.P. Acthar Gel (currently ANI Pharmaceuticals). It carries approximately 19 FDA-labelled indications including infantile spasms (its strongest evidence base), nephrotic syndrome, multiple sclerosis relapses, and rheumatic disorders. Acthar Gel has been at the centre of major pricing and legal controversies. The price rose from approximately $40 per vial in 2001 to over $40,000, driven by successive acquisitions and orphan-like positioning despite broad labelling. The former manufacturer Mallinckrodt agreed to a $260 million settlement over antitrust concerns. Clinically, the strongest evidence supports its use in infantile spasms, where it is considered a first-line treatment. For most other indications, debate continues over whether it offers meaningful advantages over far less expensive oral corticosteroids.
Enfuvirtide is marketed as Fuzeon (approved March 2003). It requires twice-daily subcutaneous injections, and injection-site reactions occur in nearly all patients (98%). In clinical trials (TORO-1 and TORO-2), enfuvirtide combined with an optimised background regimen achieved significantly greater viral suppression than background regimen alone in treatment-experienced patients. Enfuvirtide represented a major advance when HIV drug resistance was a more pressing clinical challenge, but its use has declined substantially with the arrival of more convenient oral antiretrovirals. The twice-daily injection burden, injection-site reactions, high cost, and complex manufacturing (it is one of the largest synthetic peptides manufactured at scale) have limited its role to a last-resort option for patients with highly resistant HIV.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
